COST-EFFECTIVENESS OF VENETOCLAX-OBINUTUZUMAB VS. VENETOCLAX-RITUXIMAB, VENETOCLAX-OBINUTUZUMAB-IBRUTINIB, AND CHEMOIMMUNOTHERAPY IN TREATMENT-NAÏVE FIT CLL PATIENTS WITHOUT TP53 ABERRATIONS
EHA Library, Lars Ehlers,
4161708
THE GAB2 NETWORK IN ACTION: UNVEILING GAB2, GRB2, PIK3R1, AND LYN IN CHRONIC MYELOID LEUKEMIA.
EHA Library, Denise Kusma Wosniaki,
4161760